Pfizer Clarifies Covid-19 Vaccine Storage Concerns for India Market


American pharmaceutical giant Pfizer, which sought approval from India’s drug regulator Drugs Controller General of India ((DGCI) for emergency use authorisation of its coronavirus vaccine, clarified storage concerns about its vaccine.

Pfizer requires a temperature of minus 70 degrees Celsius and experts have raised questions that India’s existing cold storage facilities do not match these conditions. Pfizer told NDTV in a statement that it has “developed detailed logistical plans and tools to support effective vaccine transport, storage and temperature monitoring” and will be using different options for storage, ranging from temperature-controlled thermal shippers to refrigeration units that are commonly available in hospitals. It also said that the pricing of the vaccine will depend on the doses ordered and the advance commitments with the government.

See also  Nua partners with Deepika Padukone to transform menstrual wellness in India